Key Takeaways
- Domestic degrowth, H2 rebound promised: Domestic formulations degrew 2.4% YoY as COVID-linked products and field-force target-setting dragged, but management expects H2 to deliver more than 50% of full-year revenue and maintains at least 5% full-year India growth.
- International business carried the quarter: International formulations grew 28.5% YoY, led by the US up 44.7% and Europe up 25.2% despite currency headwinds, with near-perfect hedging protecting reported growth.
- Gross margin recovered sequentially: Gross margin improved from ~67% in Q1 to 70.5% in Q2 on better product mix, operational excellence initiatives, and easing raw material costs, though it remains 200 bps below the normal 72% level.
- Europe margin turnaround is the explicit bet: Europe EBITDA margins sit at 9.5–10% today; management targets 14–15% minimum within three quarters, driven by a Rs.150 Crore+ order book, new product approvals, and production planning efficiencies.
- What to watch next quarter: Whether Combigan profit share begins to flow, whether the domestic H2 rebound materializes as guided, and whether Europe margins show the first leg of the promised improvement.
Domestic Formulations: The H2 Rebound Bet
- COVID basket distorted the base: Anti-infectives and respiratory, which together make up 40% of domestic topline, had fallen last year, making target-setting challenging; management created separate targets excluding the COVID basket, but the field force did not push as typical, hurting primary sales.
- New products delivered a bright spot: New introductions contributed Rs.5 Crores (2.3% of topline) in Q2 FY23 vs Rs.1.7 Crores (0.8%) in Q2 FY22, the best performance in several years.
- Therapy-level divergence was sharp: Anti-infectives rose 73% QoQ in absolute terms and respiratory rose 25% QoQ, while Febrex Plus brand underperformed and COVID basket products including ATM and Karvol Plus performed much better YoY.
- Chronic portfolio is small but growing fast: Cardiac therapy grew 70% to Rs.3.5 Crores, anti-diabetic reached Rs.6.5 Crores, and sub-chronic grew 11.5% for the half year, helping offset a 13.5% decline in acute; chronic therapy now contributes ~10% of India business.
- Chronic division restructured for focus: Two chronic divisions were merged into one synergy division last year to concentrate on products that matter, with management being selective about launches rather than chasing crowded markets.
- Full-year India guidance held at 5%+: Management guides at least 5% reported growth over last year's Rs.803 Crores, implying Rs.840–845 Crores, with H2 expected to contribute more than 50% of full-year revenue versus the typical 45%.
- Beyond FY23, a new base resets growth: By end of 2023, the COVID-impact business will be fully lapped and a new base established; management expects the industry to deliver higher single-digit growth with some double-digit quarters, and Indoco to beat those numbers.
Aditi Panandikar: "This was a very challenging year for us for target setting for India business... we have now revised it strategically for the second half and I therefore expect much better performance."
International Formulations: US and Europe Drive Growth
- US business surged 44.7% YoY: US revenues grew strongly in both Q2 and H1, driven by three new launches (one ophthalmic, two injectables) and the entry of Brinzolamide suspension ophthalmic into the market.
- Lacosamide injection held pricing power: Indoco enjoyed three months as the only generic for Lacosamide injections; the market size expanded from Rs.4.3 Crores to Rs.4.9 Crores, indicating prices did not come under pressure even after two additional approvals.
- Combigan launch by Teva is now live: Teva launched Combigan as the third player besides the innovator approximately one month before the call; no sales impact in Q2, with profit share to be recognized when Teva sells, and contribution expected from Q3 FY23 onwards.
- Brinzolamide profit share still ramping: Total US profit share was ~Rs.7 Crores across many products; Brinzolamide's contribution was not appreciable as the product is settling down post-relaunch, with more expected in coming quarters.
- Europe grew 25.2% YoY despite currency headwinds: Constant-currency growth was pound +2%, euro +11%, dollar +13%, with near-perfect hedging protecting reported numbers.
- Europe hedging is locked in through FY2024: The pound was hedged when it was over Rs.100 to a rupee and the euro at an average rate of around 90; management described the strategy as near-perfect but cautioned that things could go wrong in subsequent quarters.
- Europe order book supports margin expansion: An order book exceeding Rs.150 Crores enables cost control and production planning across Baddi and Goa plants; new product approvals for neurotic pain and epilepsy capsules add to the pipeline.
- Full-year US revenue target of at least Rs.300 Crores: The US pipeline is increasingly weighted toward complex injectables, suspension ophthalmics, and sustained-release solids, with the largest contribution to new filings coming from injectables followed by ophthalmics.
Sundeep Bambolkar: "We deployed a very careful strategy while hedging the euro and pound with the result our hedging has been near to perfect. I would not bores too much about it because things could go wrong in subsequent quarters, so I will be a very little careful on my words, but at least for the time being we are on good track."
Margin Trajectory: Gross Margin Recovery, Europe the Lever
- Gross margin improved 300+ bps sequentially: Gross margin moved from 67–67.5% in Q1 to 70.5% in Q2, driven by changing product mix in Europe, an operational excellence team set up under the CFO and operations head, raw material costs starting to normalize, and alternate vendor development for externally manufactured APIs.
- Gross margin still 200 bps below normal: The 70.5% level compares to a normal 72%, with management expecting sequential improvement as the US business grows and COGS moves downward.
- Europe EBITDA margins are the explicit turnaround story: Current EBITDA margins of 9.5–10% are expected to improve to 14–15% minimum within three quarters, driven by order book strength, new product approvals, and production planning efficiencies.
- Full-year EBITDA margin guidance maintained at ~20%: Management expressed confidence in H2 profitability, citing international plus others now at almost 50% of topline, good ramp-up expected, COGS coming under control, and growing contribution from US and India business.
- Three-year margin ambition exceeds 25%: Management expressed confidence that margins can beat 25% in three years.
- Other expenditure included a one-time hit: Other expenses rose ~20% YoY, but this included a one-time indirect tax charge of ~Rs.7 Crores; otherwise expenses were described as under control.
- Other operating income boosted by exchange gains: Higher by Rs.7.5–8 Crores, including an incremental exchange gain of Rs.13 Crores, which management characterized as part of business, not speculative.
Sundeep Bambolkar: "Right now margins are tottering around 9.5%, 10% of EBITDA, but going ahead within three quarters from now onwards I hope to see EBITDAs of 14%, 15% minimum."
Operational Milestones: SAP Go-Live and Pipeline Build
- SAP S4 Hana went live successfully: The system went live on August 5, 2022; three months of sales revenue have been closed through it and the first quarterly results were produced from the system, described as completely satisfying and highly successful.
- First complex injectable nearing exhibit batches: Developed by R&D, the product will go into plants for exhibit batches in January/February; a new manufacturing line has been purchased and is being installed this month.
- South Africa business revived: All three Goa plant approvals are now in place; the business is running at Rs.3.5 Crores per quarter with profitability in creams, ointments, and liquid orals much higher than solid dosage; tender applications have been submitted with announcements expected shortly.
- CRO expansion underway: Additional capacity is expected in a couple of months, which will allow doubling of external business; currently 65% of CRO capacity is consumed internally for Indoco's own products, leaving only ~40% available for external sales.
- R&D spend to stabilize around 5% of sales: The absolute quantum will grow with revenue; management noted that Indoco has become strong enough to have its own product pipeline rather than relying on co-development partners.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India full-year revenue growth | At least 5% reported growth over FY22 (Rs.840–845 Crores) | FY23 |
| H2 domestic revenue skew | H2 to contribute more than 50% of full-year India revenue (vs typical 45%) | FY23 |
| Europe EBITDA margin improvement | From 9.5–10% to 14–15% minimum | Within three quarters |
| Full-year US revenue | At least Rs.300 Crores | FY23 |
| Full-year EBITDA margin | ~20% | FY23 |
| South Africa quarterly revenue | Double from Rs.3.5 Crores per quarter | Within two quarters |
| South Africa tender business | ~Rs.60 Crores per annum | Starting April 2023 |
| Micro Labs plant utilization | 70% occupancies | By December 2023 |
| CRO external business capacity | Double from current levels | In a couple of months |
| Capex | Controlled to Rs.125 Crores | FY23 |
| Long-term margin ambition | Beat 25% | In three years |
| Long-term revenue ambition | Rs.5,000 Crores | In five years |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Net revenue | ₹404.6 cr, +8.6% YoY |
| Domestic formulation revenue | ₹208.5 cr, -2.4% YoY; domestic branded business 55% of total revenue |
| International formulation revenue | ₹174 cr, +28.5% YoY |
| US business revenue | ₹69.3 cr, +44.7% YoY |
| Europe business revenue | ₹74.7 cr, +25.2% YoY |
| Emerging markets revenue | ₹26.5 cr, +9.5% YoY |
| API business revenue | ₹18.3 cr, -7.1% YoY |
| EBITDA margin | 21.7%, vs 23.2% YoY; EBITDA ₹87.8 cr vs ₹86.3 cr |
| PAT margin | 12.3%, vs 11.2% YoY; PAT ₹49.6 cr vs ₹41.6 cr |
| EPS | ₹5.39, vs ₹4.51 YoY |
| Gross margin | 70.5%, vs 67–67.5% QoQ; down 200 bps YoY from normal level of 72% |
| India business full-year growth guidance | At least 5%, on base of ₹803 cr, implying ₹840–845 cr |
| US business full-year revenue expectation | At least ₹300 cr |
| Europe business order book | ₹150 cr plus as of call date |
| Europe business EBITDA margin | 9.5–10%, expected to improve to 14–15% within three quarters |
| New product introductions contribution | ₹5 cr, 2.3% of domestic topline vs 0.8% YoY |
| Chronic therapy contribution | ~10% of India business; H1 chronic sales ~₹50 cr |
| Capex for FY23 | ₹125 cr projected; H1 capex ₹90 cr+ |
| R&D spend | 5% of sales, expected to stabilize around this level |
| MR productivity | 3.5, improved from 3 over last couple of years |
| One-time indirect tax expense | ₹7 cr, recognized in other expenses; excluding this, other expenses would have been ₹112 cr |
| Incremental exchange gain in other operating income | ₹13 cr |
| Effective domestic price hike | ~6% |
| US new launches in H1 FY23 | 3 (one ophthalmic, two injectable) |
| South Africa quarterly revenue | ₹3.5 cr, expected to double in two quarters; earlier tender business ₹60–70 cr per annum |
| Lacosamide injection US market size | ₹4.9 cr, grew from ₹4.3 cr within three months of Indoco's entry |
| Vision target | ₹5,000 cr in five years, set by first-line team |